Qiagen (NYSE:QGEN) Trading 2.2% Higher - What's Next?

Qiagen (NYSE:QGEN - Get Free Report)'s share price rose 2.2% during trading on Monday . The company traded as high as $39.31 and last traded at $39.10. Approximately 359,589 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 1,093,214 shares. The stock had previously closed at $38.26.

Analyst Ratings Changes

A number of brokerages recently weighed in on QGEN. UBS Group decreased their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Robert W. Baird lowered Qiagen from an "outperform" rating to a "neutral" rating and lowered their price target for the stock from $52.00 to $42.00 in a report on Wednesday, February 19th. Morgan Stanley restated an "equal weight" rating and issued a $46.67 price target (down previously from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Redburn Atlantic downgraded Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Finally, Baird R W lowered Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $47.71.

Qiagen Stock Up 4.8 %

The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The company has a market capitalization of $9.33 billion, a PE ratio of 116.88, a price-to-earnings-growth ratio of 2.39 and a beta of 0.62. The firm's 50-day simple moving average is $39.75 and its 200 day simple moving average is $41.81.

Remove Ads

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. As a group, equities research analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

A number of institutional investors and hedge funds have recently modified their holdings of QGEN. Charles Schwab Investment Management Inc. boosted its position in Qiagen by 3.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 57,513 shares of the company's stock worth $2,621,000 after purchasing an additional 1,844 shares in the last quarter. State Street Corp increased its holdings in Qiagen by 3.9% during the 3rd quarter. State Street Corp now owns 2,380,008 shares of the company's stock valued at $108,457,000 after acquiring an additional 90,181 shares in the last quarter. National Bank of Canada FI raised its position in Qiagen by 1.2% during the third quarter. National Bank of Canada FI now owns 25,636 shares of the company's stock worth $1,155,000 after acquiring an additional 308 shares during the last quarter. MML Investors Services LLC raised its position in Qiagen by 9.7% during the third quarter. MML Investors Services LLC now owns 30,202 shares of the company's stock worth $1,376,000 after acquiring an additional 2,674 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Qiagen by 170.6% in the third quarter. Barclays PLC now owns 1,849,004 shares of the company's stock valued at $84,259,000 after purchasing an additional 1,165,594 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.